rVSVΔG-ZEBOV-GP

AXP000205.1 · Vaccine

Platform
vesicular stomatitis virus (Indiana, G-deleted, ZEBOV GP-bearing)
Targets
Zaire ebolavirus GP
Originator
Public Health Agency of Canada (National Microbiology Laboratory)
Sponsor
Merck Sharp & Dohme

Names

NameTypeSource
rVSVΔG-ZEBOV-GPpreferred name, synonymcurator, curator
Ervebobrandfda
Ebola Zaire Vaccine, Live ambiguoussynonymfda
rVSV-ZEBOVsynonymcurator

Virus

Role
Vaccine vector
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
Indiana, rVSVΔG
Replication
replicating
Modifications
VSV glycoprotein (G) gene deleted and replaced by the Zaire ebolavirus (Kikwit 1995) surface glycoprotein gene
Transgenes
Zaire ebolavirus GP
Route
intramuscular
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2019-11-11conditionalErveboActive immunisation against Ebola virus disease caused by Zaire ebolavirus (conditional authorisation)source
FDAUS2019-12-19approvedErveboPrevention of disease caused by Zaire ebolavirus, from 12 months of agesource
EMAEU2021-01-14approvedErveboActive immunisation against Ebola virus disease caused by Zaire ebolavirus, from 1 year of age (switched from conditional to standard)source

Clinical trials (14)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05202288Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy VolunteersNot yet recruitingPhase 22027-012027-08132Ebola Virus Disease
NCT07903350BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination StrategiesRecruitingPhase 42026-09-192027-0620000Bundibugyo Virus Disease (BVD); Ebola
NCT06841614EBOla Post-Exposure ProphylaxisNot yet recruitingPhase 32026-092027-08-01160Ebola Virus Disease
NCT05959421Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for ExposureWithdrawnPhase 32026-062027-120Ebola Vaccine
NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Active not recruitingPhase 42025-12-012026-1140Ebola Virus Disease
NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCRecruitingPhase 32025-02-252026-10624Ebola Virus Disease
NCT06587503Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster DosesUnknownPhase 42024-102024-1272COVID-19; Ebola Virus Disease
NCT06100913Immunology of Ebola VaccineActive not recruitingPhase 22024-08-062027-08-3130Ebola Virus Disease
NCT04822376Prophylaxis Vaccine Antibodies EbolaUnknownPhase 22021-10-172022-04250Ebola Virus Disease
NCT05130398Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, GabonCompletedPhase 1/22021-04-092021-09-08120Ebola Virus Disease
NCT03161366Providing Additional Information on the Safety and Effectiveness of an Ebola VaccineCompletedPhase 32018-05-282018-07-14500Ebola Virus Disease
NCT03031912African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-EbolaCompletedPhase 22017-08-012023-03-03251Ebola
NCT02876328Partnership for Research on Ebola VACcinationsCompletedPhase 22017-03-272019-12-244789Ebola Virus Disease
NCT02283099Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)CompletedPhase 12014-112015-1130Hemorrhagic Fever, Ebola
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT02503202Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)CompletedPhase 32015-08-172016-05-021197Prevention of Ebola Infectionname in title: rVSV-ZEBOV

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT07903350new trialBRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41610955A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV).Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2026name in title: rVSVΔG-ZEBOV-GP
PMID 41616038Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial.PLoS neglected tropical diseases2026cited by trial NCT02876328
PMID 42326817Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.medRxiv : the preprint server for health sciences2026cited by trial NCT02876328
PMID 42332598When it could have been prevented: A maternal death from postpartum hemorrhage due to genital tract lesions complicated by urinary fistula in an Ebola treatment unit in DR Congo.BMC pregnancy and childbirth2026name in abstract: rVSV-ZEBOV
PMID 42567171Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.The lancet. HIV2026cited by trial NCT03031912
PMID 39559990Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.Emerging microbes & infections2025cited by trial NCT02876328
PMID 39718991Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies.The Journal of infectious diseases2025name in title: rVSVΔG-ZEBOV-GP
PMID 40011840Maternal and fetal survival following Ebola, HIV and Malaria co-infection in the first trimester of gestation in resource-limited setting in Democratic Republic of Congo.BMC pregnancy and childbirth2025name in abstract: rVSV-ZEBOV
PMID 40125488Neonatal Survival Following Spontaneous Maternal Recovery From Ebola Virus Disease in a Resource-Limited Setting in Western Democratic Republic of the Congo.Case reports in infectious diseases2025name in abstract: rVSV-ZEBOV
PMID 40976661Safety and immunogenicity of rVSVΔG-ZEBOV-GP vaccination when dosed concurrent with mRNA COVID-19 vaccine booster doses in healthy African adults (EbolaCov): protocol for a phase IV, single-centre, single-blinded, randomised controlled trial.BMJ open2025cited by trial NCT06587503
PMID 37967326Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2024cited by trial NCT02876328
PMID 39121969Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon.The Journal of infection2024name in title: rVSVΔG-ZEBOV-GP
PMID 39227399Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.Nature communications2024cited by trial NCT02876328
PMID 39374605Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.The Lancet. Microbe2024name in title: rVSVΔG-ZEBOV-GP
PMID 36725433Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).Vaccine2023name in title: rVSVΔG-ZEBOV-GP
PMID 36208978Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.Vaccine2022name in title: rVSVΔG-ZEBOV-GP
PMID 36516078Randomized Trial of Vaccines for Zaire Ebola Virus Disease.The New England journal of medicine2022cited by trial NCT02876328
PMID 33485369Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.Trials2021cited by trial NCT02876328
PMID 33789012Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease.The New England journal of medicine2021name in abstract: rVSV-ZEBOV
PMID 34128975Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study.Journal of travel medicine2021name in title: rVSV-ZEBOV
PMID 32017677Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola.Emerging infectious diseases2020name in abstract: rVSVΔG-ZEBOV-GP
PMID 32093984Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection.Vaccine2020name in abstract: rVSV-ZEBOV
PMID 32499064Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.Vaccine2020name in abstract: rVSVΔG-ZEBOV-GP
PMID 30266489Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.Vaccine2019name in title: rVSV-ZEBOV
PMID 30452666Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.The Journal of infectious diseases2019cited by trial NCT02283099
PMID 30561672PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia.The Journal of infectious diseases2019name in title: rVSVΔG-ZEBOV-GP
PMID 31505665Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults.The Journal of infectious diseases2019name in title: rVSVΔG-ZEBOV-GP
PMID 31591605Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.Nature medicine2019name in title: rVSV-ZEBOV
PMID 29627147Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.The Lancet. Infectious diseases2018name in title: rVSV-ZEBOV
PMID 25830322A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.The New England journal of medicine2017name in abstract: rVSVΔG-ZEBOV-GP
PMID 28017403Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).Lancet (London, England)2017name in abstract: rVSV-ZEBOV
PMID 28434944Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.EBioMedicine2017cited by trial NCT02283099
PMID 28549145Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.The Journal of infectious diseases2017name in abstract: rVSVΔG-ZEBOV-GP
PMID 28630358Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2017name in abstract: rVSVΔG-ZEBOV-GP
PMID 28647166Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.Vaccine2017cited by trial NCT02283099
PMID 28854372Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.Cell reports2017name in title: rVSV-ZEBOV
PMID 28985239Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.PLoS medicine2017name in title: rVSVΔG-ZEBOV-GP
PMID 25629663A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.The New England journal of medicine2016name in abstract: rVSV-ZEBOV
PMID 25830326Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.The New England journal of medicine2016cited by trial NCT02283099
PMID 25694650Risk of Misinterpretation of Ebola Virus PCR Results After rVSV ZEBOV-GP Vaccination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2015name in title: rVSV-ZEBOV
PMID 26248510The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.The Lancet. Infectious diseases2015name in abstract: rVSV-ZEBOV
PMID 26248676Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.Lancet (London, England)2015name in abstract: rVSV-ZEBOV
PMID 26659569Ebola vaccine R&D: Filling the knowledge gaps.Science translational medicine2015cited by trial NCT02283099

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 41467787Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus.mBio2026name in abstract: Ervebo
PMID 41519695Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease.BMC infectious diseases2026name in abstract: Ervebo
PMID 41526916Understanding perceptions towards COVID-19 vaccination and strategies to increase vaccine uptake among Ebola- affected communities in North Kivu, Democratic Republic of the Congo: a qualitative study.BMC public health2026name in abstract: rVSV-ZEBOV
PMID 41634853Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine?Tropical diseases, travel medicine and vaccines2026name in abstract: rVSV-ZEBOV
PMID 41746065Global Health Preparedness Frameworks and Recombinant Vaccine Platforms: A Public Health Perspective on Regulations and System Readiness.Vaccines2026name in abstract: rVSV-ZEBOV
PMID 41819639Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection.Vaccine2026name in abstract: Ervebo
PMID 41874168In vitro cellular tropism and immunomodulatory response to rVSVΔG-ZEBOV-GP in human cells derived from tissues associated with adverse events.Microbiology spectrum2026name in title: rVSVΔG-ZEBOV-GP
PMID 41911664Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance.Emerging infectious diseases2026name in title: Ervebo
PMID 42221441[Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access].Medecine tropicale et sante internationale2026name in abstract: rVSVΔG-ZEBOV-GP
PMID 42245043Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.medRxiv : the preprint server for health sciences2026name in abstract: rVSVΔG-ZEBOV-GP
PMID 42376411Ebola virus disease: A persistent challenge in global health security.Open veterinary journal2026name in abstract: rVSV-ZEBOV
PMID 42476156Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak.The Lancet. Infectious diseases2026name in title: rVSVΔG-ZEBOV-GP
PMID 42542607Closing Critical Gaps in the 2026 Bundibugyo Ebola Response: Five Actionable Priorities.Cureus2026name in abstract: rVSV-ZEBOV
PMID 42623404Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings.PloS one2026name in abstract: Ervebo
PMID 42641631Bundibugyo virus glycoprotein seroreactivity following recombinant vesicular stomatitis virus-Zaire Ebola virus glycoprotein vaccination in outbreak-affected populations of the Democratic Republic of the Congo: a longitudinal cohort study.Lancet (London, England)2026name in abstract: rVSVΔG-ZEBOV-GP
PMID 42685736Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study.The Lancet. Infectious diseases2026name in abstract: rVSV-ZEBOV
PMID 42697215Cross-reactive Bundibugyo antibody responses in Guinean survivors of Ebola virus and recipients of rVSVΔG-ZEBOV-GP (Ervebo) in an outbreak setting.The Lancet. Infectious diseases2026name in title: rVSVΔG-ZEBOV-GP
PMID 42721983rVSVΔG-ZEBOV-GP vaccine-induced seroreactivity to Bundibugyo virus: a cross-protection dilemma.Lancet (London, England)2026name in title: rVSVΔG-ZEBOV-GP
PMID 42728358The 2026 Bundibugyo Ebola Outbreak: A Warning for Global Preparedness for Future Epidemics.Iranian biomedical journal2026name in abstract: rVSV-ZEBOV
PMID 42742181Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children.Nature medicine2026name in abstract: rVSV-ZEBOV
PMID 42776645Ebola Virus Disease in the Era of One Health and Global Preparedness: Evolving Epidemiology, Genomic Surveillance, and Future Challenges.Infectious disease reports2026name in abstract: rVSV-ZEBOV
PMID 42859161From Ebola response to adaptable preparedness beyond a single virus.Tropical medicine and health2026name in abstract: Ervebo
PMID 42869053Cross-reactive T-cell responses against BDBV in humans after rVSVΔG-ZEBOV-GP vaccination.The Lancet. Infectious diseases2026name in title: rVSVΔG-ZEBOV-GP
PMID 42869683rVSV-ΔG-EBOV-GP-Nipah-G (also designated PHV02) replication-competent, recombinant vesicular stomatitis virus vaccine for prevention of Nipah virus disease: Standardized template with key considerations for a risk/benefit assessment.Vaccine2026name in abstract: Ervebo
PMID 42880328Cross-neutralisation of authentic Ebola virus and Bundibugyo virus following natural infection or Ervebo vaccination.The Lancet. Infectious diseases2026name in title: Ervebo
PMID 42887369Early detection of immunoglobulin A against a vaccine backbone protein enables fast, durable, and objective identification of individuals vaccinated against Ebola virus.EBioMedicine2026name in abstract: rVSVΔG-ZEBOV-GP
PMID 42890496Resurgence of Ebola in the Democratic Republic of Congo: Lessons Learned and Future Directions.Health science reports2026name in abstract: rVSVΔG-ZEBOV-GP
PMID 39805421Vaccination strategies for Ebola in the democratic republic of Congo: the WHO-Ebola modeling collaboration.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2025name in abstract: rVSV-ZEBOV
PMID 40143270Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.Viruses2025name in title: rVSVΔG-ZEBOV-GP
PMID 40143273rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.Viruses2025name in title: rVSVΔG-ZEBOV-GP
PMID 40215567Corrigendum to "Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda" [Vaccine 24 (22) (2024) 126031].Vaccine2025name in title: rVSVΔG-ZEBOV-GP
PMID 40375337Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo.Virology journal2025name in abstract: rVSV-ZEBOV
PMID 40706506Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC.Vaccine2025name in title: rVSV-ZEBOV
PMID 40902221Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.Vaccine2025name in abstract: Ervebo
PMID 40966976Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537].Vaccine2025name in title: rVSV-ZEBOV
PMID 41744005Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.Frontiers in immunology2025name in abstract: rVSVΔG-ZEBOV-GP
PMID 37722397Prevention and post-exposure management of occupational exposure to Ebola virus.The Lancet. Infectious diseases2024name in abstract: rVSV-ZEBOV
PMID 37766672Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS-CoV-2.Biotechnology journal2024name in abstract: rVSVΔG-ZEBOV-GP
PMID 38305150Translational success of fundamental virology: a VSV-vectored Ebola vaccine.Journal of virology2024name in abstract: rVSVΔG-ZEBOV-GP
PMID 38315357Production and Purification of Filovirus Glycoproteins.Methods in molecular biology (Clifton, N.J.)2024name in abstract: Ervebo
PMID 38340736Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo.The Lancet. Infectious diseases2024name in title: rVSVΔG-ZEBOV-GP
PMID 38489257Recent advances in the treatment of Ebola disease: A brief overview.PLoS pathogens2024name in abstract: Ervebo
PMID 38662631Use of Ebola Vaccines - Worldwide, 2021-2023.MMWR. Morbidity and mortality weekly report2024name in abstract: rVSVΔG-ZEBOV-GP
PMID 38880693Knowledge, attitudes, and practices and long-term immune response after rVSVΔG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.Vaccine2024name in title: rVSVΔG-ZEBOV-GP
PMID 39118744National burden of Ebola virus disease in Democratic Republic of the Congo: the urgency to act.Annals of medicine and surgery (2012)2024name in abstract: rVSV-ZEBOV
PMID 39178865Assessing the real-world effectiveness of the rVSV-ZEBOV vaccine.The Lancet. Infectious diseases2024name in title: rVSV-ZEBOV
PMID 39178866Effectiveness of rVSV-ZEBOV vaccination during the 2018-20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study.The Lancet. Infectious diseases2024name in title: rVSV-ZEBOV
PMID 39511527rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).BMC medicine2024name in title: rVSV-ZEBOV
PMID 39693543Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination.The New England journal of medicine2024name in title: rVSV-ZEBOV
PMID 39749221New reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs.Frontiers in chemistry2024name in abstract: Ervebo
PMID 35169298Self-replicating vehicles based on negative strand RNA viruses.Cancer gene therapy2023name in abstract: Ervebo
PMID 36154608Gene Therapy Cargoes Based on Viral Vector Delivery.Current gene therapy2023name in abstract: Ervebo
PMID 36992407Viral Vectors in Gene Therapy: Where Do We Stand in 2023?Viruses2023name in abstract: Ervebo
PMID 37061918Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.Cell reports2023name in abstract: rVSVΔG-ZEBOV-GP
PMID 37171813A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.The Journal of infectious diseases2023name in abstract: Ervebo
PMID 37243081Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.Vaccines2023name in title: rVSV-ZEBOV
PMID 37290053A Recombinant Vesicular Stomatitis Virus-Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection.The Journal of infectious diseases2023name in abstract: Ervebo
PMID 37661067Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023name in abstract: rVSV-ZEBOV
PMID 38022684Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts.Frontiers in immunology2023name in abstract: Ervebo
PMID 38162033Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.iScience2023name in title: rVSVΔG-ZEBOV-GP
PMID 38235127Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America.Frontiers in immunology2023name in title: rVSVΔG-ZEBOV-GP
PMID 34914048Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2.Methods in molecular biology (Clifton, N.J.)2022name in title: Ervebo
PMID 35012339Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.mBio2022name in abstract: rVSV-ZEBOV
PMID 35110410Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.Proceedings of the National Academy of Sciences of the United States of America2022name in title: rVSVΔG-ZEBOV-GP
PMID 35202354Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021.MMWR. Morbidity and mortality weekly report2022name in abstract: rVSVΔG-ZEBOV-GP
PMID 35544042Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.The Lancet. Microbe2022name in title: rVSVΔG-ZEBOV-GP
PMID 35545650Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach.Scientific reports2022name in abstract: Ervebo
PMID 35622847A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.PLoS neglected tropical diseases2022name in abstract: Ervebo
PMID 35759511Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.PLoS pathogens2022name in abstract: Ervebo
PMID 35866579Safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: experience from a French pre-travel clinic.Journal of travel medicine2022name in title: rVSV-ZEBOV
PMID 36091016Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies.Frontiers in immunology2022name in abstract: rVSV-ZEBOV
PMID 36146524Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines.Vaccines2022name in title: rVSVΔG-ZEBOV-GP
PMID 33417593Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports2021name in abstract: rVSVΔG-ZEBOV-GP
PMID 33498214Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine.Vaccines2021name in abstract: rVSVΔG-ZEBOV-GP
PMID 33501447Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine.bioRxiv : the preprint server for biology2021name in abstract: rVSV-ZEBOV
PMID 33536172Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization.Journal of virology2021name in abstract: rVSV-ZEBOV
PMID 33594388Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.Drugs of today (Barcelona, Spain : 1998)2021name in abstract: Ervebo
PMID 33668698Development of Pandemic Vaccines: ERVEBO Case Study.Vaccines2021name in title: Ervebo
PMID 33719915High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.Emerging microbes & infections2021name in abstract: Ervebo
PMID 33782211Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays.The American journal of tropical medicine and hygiene2021name in title: rVSVΔG-ZEBOV-GP
PMID 33795759Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO.Scientific reports2021name in title: Ervebo
PMID 33837958Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.Biotechnology and bioengineering2021name in abstract: rVSV-ZEBOV
PMID 33873076Ebola virus disease: current vaccine solutions.Current opinion in immunology2021name in abstract: rVSV-ZEBOV
PMID 33937326Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.Frontiers in molecular biosciences2021name in abstract: Ervebo
PMID 34013349Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein.The Journal of infectious diseases2021name in abstract: rVSVΔG-ZEBOV-GP
PMID 34270366Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis.Human vaccines & immunotherapeutics2021name in abstract: rVSVΔG-ZEBOV-GP
PMID 34335620Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.Frontiers in immunology2021name in abstract: rVSV-ZEBOV
PMID 34343363Conserved immunogenic peptides of Ebola glycoprotein elicit immune response in human peripheral blood mononuclear cells.Microbiology and immunology2021name in abstract: Ervebo
PMID 34535490'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.BMJ global health2021name in abstract: rVSV-ZEBOV
PMID 34696295Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.Vaccines2021name in abstract: Ervebo
PMID 34749265Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.Current opinion in virology2021name in abstract: Ervebo
PMID 35544244Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.The Lancet. Microbe2021name in title: rVSVΔG-ZEBOV-GP
PMID 31784751Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2020name in title: rVSV-ZEBOV
PMID 31979026Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas.Vaccines2020name in title: rVSV-ZEBOV
PMID 32006630Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.Journal of biotechnology2020name in title: rVSV-ZEBOV
PMID 32030996Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions.Future microbiology2020name in title: rVSVΔG-ZEBOV-GP
PMID 32081445Examination of the effect of agitation on the potency of the Ebola Zaire vaccine rVSVΔG-ZEBOV-GP.Vaccine2020name in title: rVSVΔG-ZEBOV-GP
PMID 32195130Titration methods for rVSV-based vaccine manufacturing.MethodsX2020name in abstract: rVSV-ZEBOV
PMID 32210083Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV.Vaccines2020name in abstract: Ervebo
PMID 32243796A Vaccine against Ebola Virus.Cell2020name in abstract: Ervebo

NIH grants

ProjectTitleOrganisationPIYearsLinked by
F30AI181340Evaluating the impact of malaria on immunogenicity of the Ebola virus vaccineUNIVERSITY OF IOWAELLIFF, JONAH2024–2026name in abstract: Ervebo
R01AI160226Preclinical development of a vaccine for Nipah virusUNIVERSITY OF TEXAS MED BR GALVESTONGEISBERT, THOMAS WILLIAM2021–2026name in abstract: Ervebo
R56AI192635Evaluation of a pan-Filovirus virus-like particle (VLP) vaccine.CINCINNATI CHILDRENS HOSP MED CTRSINGH, KARNAIL2026–2026name in abstract: rVSV-ZEBOV
ZIAAI000936Pathogenesis, Treatment and Prevention of Emerging Infectious DiseasesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESLANE, CLIFFORD2025–2025name in abstract: rVSV-ZEBOV
ZIAAI000984Influenza and Emerging Infectious DiseasesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESDAVEY, RICHARD2023–2025name in abstract: rVSV-ZEBOV
UH2AI174415Defining the effect of Plasmodium infection on Ebola virus vaccine efficacyUNIVERSITY OF IOWAMAURY, WENDY JEAN2023–2024name in abstract: Ervebo
ZIAAI001254Immunobiology, molecular virology and countermeasures of highly pathogenic virusesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESMARZI, ANDREA2020–2020name in abstract: Ervebo
ZIAAI001163CAP: Trivalent Filovirus Vaccine for Pre- and Post-Exposure VaccinationNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESFELDMANN, HEINRICH2017–2017name in abstract: rVSV-ZEBOV
R43CK000494MagaVax vaccine for EbolaMULTIMERIC BIOTHERAPEUTICS, INC.KORNBLUTH, RICHARD SYD2016–2016name in abstract: rVSV-ZEBOV

Notes

Replication-competent rVSV whose own glycoprotein gene is replaced by the Zaire ebolavirus (Kikwit 1995) GP; marketed as Ervebo. EMA authorisation was conditional on 2019-11-11 and converted to a standard marketing authorisation on 2021-01-14. Licensed in several African countries after WHO prequalification (not recorded here for lack of an agency record opened). Merck development code V920 and the earlier NewLink code BPSC-1001 are widely used but were not confirmed on a page opened for this pass, so they are not listed as aliases.

How to cite

rVSVΔG-ZEBOV-GP (AXP000205.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000205.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.